U.S. Markets closed

Valeant Pharmaceuticals before Its Q2 2018 Earnings

Daniel Collins
Valeant Pharmaceuticals before Its Q2 2018 Earnings

Valeant Pharmaceuticals (VRX), now known as Bausch Health Companies (BHC), generated revenues of $2 billion in the first quarter compared to $2.1 billion in the first quarter of 2017, reflecting a 5% YoY (year-over-year) decline.